Twitter Facebook LinkedIn YouTube

Medexus Pharmaceuticals (TSXV:MDP) New Listing

Video Platform Video Management Video Solutions Video Player

The name change follows Pediapharm’s recent acquisition of Medexus Inc., a Canadian pharmaceutical innovator with strategic partnerships in key international markets.

Additional Information:

Company: Medexus Pharmaceuticals
Website: http://www.medexusinc.com
Stock Symbol: TSXV: MDP
Date Published: Dec 20, 2018
Transcript: Available

Video Transcript:

I’m Samantha Deutscher for Investmentpitch Media

Medexus Pharmaceuticals is one of the latest new listings on the TSX Venturte Exchange, trading under the symbol “MDP”, having previously traded as Pediapharm.

The name change follows Pediapharm’s recent acquisition of Medexus Inc., a Canadian pharmaceutical innovator with strategic partnerships in key international markets.

The total consideration paid by Pediapharm for Medexus is approximately CDN$23 million, which was satisfied through the issuance of shares.

Pediapharm also recently completed the acquisition Medac Pharma, a privately held specialty pharmaceutical company based in Chicago, focusing primarily in the area of rheumatology in the United States.

The total consideration payable by Pediapharm for Medac Pharma is up to US$50 million, of which a cash payment of US $13.1 million was paid on closing, together with equity and other agreed-upon adjustments.

Please refer to the news release issued on October 16th for more details.

Ken d'Entremont was appointed CEO following the company's acquisition of Medexus, of which he was the founder, President and CEO.

Mr d’Entremont brings more than 30 years of experience in the pharmaceutical industry.

Newly appointed Chairman, Peter van der Velden is the Managing General Partner of Lumira Ventures and has significant private and public market experience in the pharmaceutical industry.

Peter van der Velden commented: “I am very pleased to take on this role and to have the opportunity to work with the Company’s outstanding team of proven pharmaceutical executives as they strive to leverage the Company’s portfolio of best-in-class products. The Company is well positioned to efficiently integrate the operations of Medexus and Medac Pharma and to execute on its growth strategies in each of its key markets.”

Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics.

The leading products are Rasuvo and Metoject, a unique formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases, and Rupall, an innovative allergy medication with a unique mode of action.

For more information, please visit the company’s website at www.medexusinc.com, contact Ken d’Entremont, CEO, at 905-676-0003 or email ken.dentremont@medexus.ca.

Investor relations is handled by Frank Candido of Direct Financial Strategies and Communications, who can be reached at at 514-969-5530 or email directMTL@gmail.com.

I’m Samantha Deutscher for Investmentpitch Media